Document is current
Any future updates will be listed below
-
Authors
Griffith, Bartley P.
Grazioli, Alison
Singh, Avneesh K. https://orcid.org/0000-0002-8701-2260
Tully, Andy
Galindo, Javier
Saharia, Kapil K. https://orcid.org/0000-0002-5116-0042
Shah, Aakash
Strauss, Erik R. https://orcid.org/0000-0002-6424-9441
Odonkor, Patrick N.
Williams, Brittney
Silverman, Henry J.
Burke, Allen
Drachenberg, Cinthia B. https://orcid.org/0000-0002-3104-5661
Wells, Chris L.
Dickfeld, Timm
Hong, Susie N.
Hicks, Albert J. III
Ananthram, Manjula
Gupta, Anuj
Christenson, Robert H.
Tamburro, Lo https://orcid.org/0009-0003-2571-5491
Zhang, Tianshu
Hershfeld, Alena
Lewis, Billeta
Feller, Erika D.
Kuravi, Kasinath
Sorrells, Lori
Morgand, Erwan https://orcid.org/0000-0002-1064-8770
Mezine, Fariza
Goutaudier, Valentin https://orcid.org/0000-0001-6191-6889
Rothblatt, Martine
Lau, Christine L.
Taylor, Bradley
Perrin, Steve
Loupy, Alexandre https://orcid.org/0000-0003-3388-7747
Ayares, David
Mohiuddin, Muhammad M. https://orcid.org/0000-0003-4654-783X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (AI090959)
United Therapeutics Corporation (10019787)
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 22 November 2024
First Online: 8 January 2025
Competing interests
: This study was supported by the University of Maryland Medical Center and University of Maryland School of Medicine. The source animal was provided by Revivicor, and the Tegoprubart antibody was provided by Eledon Pharmaceuticals, both in kind. CareDx and Karius analytics were provided in kind. United Therapeutics Inc. provided funding to the University of Maryland Foundation to help defray the cost of this transplant. No financial support was provided by Eledon Pharmaceuticals or XVIVO. Federal funding was used for the preclinical trial studies leading to this work. M.R. is the CEO of United Therapeutics. D.A., K.K. and L.S. are employees of Revivicor, a subsidiary of United Therapeutics. S.P. is the CEO of Eledon Pharmaceuticals. Members of the Program in Cardiac Xenotransplantation received research funding from United Therapeutics. There are no other competing interests to disclose.
